SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Second Portuguese spin out: Des Solutio

30 Oct 2018 07:00

RNS Number : 5786F
Frontier IP Group plc
30 October 2018
 

30 October 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Second Portuguese spin out Des Solutio to develop green chemistry for beauty, pharmaceutical and food industries

 

Frontier IP, a specialist in commercialising university intellectual property, today announces it is taking a 25 per cent. stake in Des Solutio (the "Company"), a company developing safer and greener alternatives to the chemicals currently used to make beauty, pharmaceutical, personal care and other products.

 

The Company has been established to develop and commercialise the research of Associate Professor Ana Rita Duarte and Dr Alexandre Paiva, of Portugal's NOVA University Lisbon, NOVA School of Science and Technology ("FCT NOVA").

 

Their research has already attracted interest from several major industrial groups, including a world-leading cosmetics company and a major pharmaceutical company. In return for its stake, Frontier IP will provide Des Solutio with a broad range of commercialisation services, including contract negotiation and identifying and working with potential industry partners to validate and scale up the technology.

 

Des Solutio is developing new methods to use Natural Deep Eutectic Solvents ("NADES") in cosmetics, nutraceuticals and other applications, to replace toxic organic solvents, such as ethanol, employed currently. Solvents are commonly used in a wide range of industries to extract active ingredients from natural matrices, such as olive oil, mint or seaweed to flavour and scent their products, and enhance the shelf-life and stability of the bioactives.

 

NADES offer many benefits over existing solvents. Found in a vast range of plants, and so compliant with a green chemistry philosophy, they are entirely derived from natural compounds such as organic acids, amino acids and sugars.

 

As there are a vast range of NADES already identified, they can be matched to specific active ingredients to extract only what is needed. There is no need to recover an active ingredient from a NADES, unlike conventional solvents, some of which are too toxic for use on skin or in foods.

 

Other advantages of the technology include improved solubility, permeability and bioavailability of the active compounds, better biodegradability than many organic solvents and greener production processes.

 

The incorporation of Des Solutio is a further sign of Frontier IP's growing momentum in Portugal. It is the Group's second spin out from FCT NOVA following NTPE, a company developing novel technology to print electronic circuits, sensors and semiconductors on to paper. The Group recently entered into a strategic partnership with the UK government's Department for International Trade in Portugal.

 

Des Solutio co-founder, Associate Professor Ana Rita Duarte said:  "We're delighted to be working with Frontier IP on developing and bringing this ground-breaking science into the commercial world. NADES have huge potential for making a host of everyday products greener and saferfor people to use."

 

Frontier IP chief executive Neil Crabb said: "We're very excited about the possibilities for Des Solutio. The technology being developed by Professor Ana Rita Duarte and Dr Alexandre Paiva has already attracted interest from major multinationals. Its incorporation as our second Portuguese spin out is further sign of our growing strength in the country."

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

Amrit Nahal (Equity Sales)

 

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABLBDGBGDBGIC
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.